Navigation Links
Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
Date:9/1/2010

SANTA MONICA, Calif., Sept. 1 /PRNewswire/ -- Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing.

"Despite the availability of several therapies for the treatment of metastatic renal cancer, there is a significant need for new renal cancer therapies," said Leonard Reyno, M.D., Senior Vice President and Chief Medical Officer at Agensys. "We believe AGS-16M8F, which is an ADC designed to deliver the potent cytotoxic agent MMAF directly to tumor cells, has the potential to provide a new therapeutic option for this disease."

The single-agent, Phase I, open-label, dose-escalation study will evaluate the safety and tolerability of AGS-16M8F in patients with renal cancer and identify the maximum tolerated dose. Secondary objectives include assessing the pharmacokinetics and antitumor activity of AGS-16M8F and identifying a recommended dose and regimen for future clinical trials. The study is designed to enroll approximately 50 patients at multiple centers in the United States.

Dr. David Stover, Vice President and Head of Research at Agensys, noted that AGS-16M8F is an ADC composed of a fully human monoclonal antibody directed to ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3), a novel cancer target identified by Agensys to be upregulated in the majority of renal cancers.

The antibody is attached to a highly potent, synthetic agent, monomethyl auristatin F (MMAF), via a non-cleavable linker using Seattle Genetics' proprietary technology. The novel linker system is designed to be stable in the bloodstream and release the potent cell-killing agent once inside antigen-expressing cancer cells. This approach is i
'/>"/>

SOURCE Astellas Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. UCI Medical Affiliates, Inc. Reports Third Quarter Results for Fiscal Year 2010
2. Kendle is First Global CRO to Achieve ISO 9001:2008 Certification in China Through Beijing Affiliate
3. US Oncology Ranks 2nd in Affiliate Member Accruals for Radiation Therapy Oncology Group
4. Surgical Care Affiliates Announces Investor Conference Call to Discuss 2009 Third Quarter Results
5. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
6. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
7. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
8. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
9. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
10. Golden Meditech Announces Plan to Issue Taiwan Depository Receipts
11. Accuray Announces Results for Fourth Quarter and Fiscal Year 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Seres Health, a clinical-stage therapeutics company ... human microbiome, announced today that Dr. David ... and Chief Scientific Officer, will be presenting at ... Chemotherapy (ICAAC). The presentation will highlight the scientific ... of bacterial spores derived from the human microbiome, ...
(Date:8/28/2014)... 28, 2014   Venaxis, Inc.  (Nasdaq:  APPY), an ... FDA clearance for and commercializing its CE Marked ... in identifying children, adolescent, and young adult patients in ... appendicitis, today announced it will present at three upcoming ... Annual Global Investment Conference being held in ...
(Date:8/28/2014)... Pa. , Aug. 28, 2014  Robotic ... patients, and media, both for the promise of ... safety. The quick deployment of surgical robots and ... are prompting facilities to evaluate their robotic surgery ... entire surgical team.    ECRI Institute ...
Breaking Medicine Technology:Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5
... shows one in five sisters of a primary ... ROCHESTER, Minn., Sept. 10 Mayo Clinic,researchers ... of patients with primary biliary cirrhosis (PBC) are,more ... in their blood. Armed with,this new information, physicians ...
... The following letter is,being released by CEL-SCI CORPORATION (Amex: ... Shareholders: The past 12 months have been the ... Drug Administration (FDA) granted us the go-,ahead for a ... drug,Multikine(R) and also granted Multikine Orphan drug designation. Following,the ...
Cached Medicine Technology:New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families 2CEL-SCI Corporation Releases Letter to Shareholders 2CEL-SCI Corporation Releases Letter to Shareholders 3CEL-SCI Corporation Releases Letter to Shareholders 4CEL-SCI Corporation Releases Letter to Shareholders 5
(Date:8/28/2014)... VA (PRWEB) August 28, 2014 Starting ... (Meso Foundation) is able to accept donations in Bitcoin, ... The Bitcoin donation page can be found at ... are accepting Bitcoin as a form of payment, we ... same,” said Meso Foundation’s chief executive officer, Melinda Kotzian. ...
(Date:8/28/2014)... August 29, 2014 UWDress.com, an internationally ... has recently unveiled its fashionable assortment of fall ... all new and old customers, the company is now ... , The company’s discounted fall bridesmaid outfits are offered ... the new collection are priced less than $190. UWDress.com’s ...
(Date:8/28/2014)... HORNE LLP has laid out the challenge ... $67 million firm has more than feel-good emotions at ... the balance. , Described by experts in the accounting ... Baby Boomers creating succession issues, poor leadership development strategies, ... culture wars within firms that are threatening the life ...
(Date:8/28/2014)... about the chance of ,overdiagnosis, through the NHS breast ... according to research published in the British Journal ... survey of around 2,200 women, Cancer Research UK scientists ... cent felt they fully understood the information given about ... cancers that would never have gone on to cause ...
(Date:8/28/2014)... Lake Worth, FL (PRWEB) August 28, 2014 ... promote National Recovery Month throughout September. This month ... of addiction treatment and mental health services. Along ... Millennium Treatment Group is helping to spread the ... Month began in 1989, honoring the work of ...
Breaking Medicine News(10 mins):Health News:Cancer Research Funding Organization Now Accepts Bitcoin Donations 2Health News:Fashionable Fall Bridesmaid Dresses From UWDress.com 2Health News:HORNE LLP Proclaims War on Accounting Firm Culture 2Health News:Some women still don't underststand 'overdiagnosis' risk in breast screening 2Health News:Millennium Treatment Group Celebrates National Recovery Month 2
... expert says, , MONDAY, July 20 (HealthDay News) -- ... of people with leukemia and other serious diseases might ... , Researchers looked at the association between the use ... "IVIg has been used safely for more than 20 ...
... , NEW YORK, July 20 Cancer Care ... multiple myeloma. Cancer Care ,s program will provide individual grants of up to ... and taxi, bus or train fare to and from their medical care. ... by a generous grant from Millennium: The Takeda Oncology Company. Cancer Care ...
... treatment of disease ,The team, led by ... at the University of Copenhagen and the Max Planck Institute ... 1,750 different proteins. "This is more than just ... known acetylation switches by a factor of six, and it ...
... of a new study of the pen and paper ... medical record system may help make electronic medical records ... they serve. "Exploring the Persistence of Paper with ... issue of the International Journal of Medical Informatics ...
... , CARY, Ill., July 20 Sage Products, Inc. has ... No. 5 on the list of the Best Medium Sized Companies to ... the Society for Human Resource Management (SHRM). Sage is a veteran-owned company ... on prevention and solving challenges in the healthcare industry. , ...
... , , ... Competition between employer-based health insurance plans and a government-sponsored public ... the majority of employers responding to a Health Care Reform Survey, ... Aon Corporation (NYSE: AOC ). What will help ...
Cached Medicine News:Health News:New Alzheimer's Treatment Could Be on the Horizon 2Health News:New Alzheimer's Treatment Could Be on the Horizon 3Health News:CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 2Health News:CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 3Health News:Can pen and paper help make electronic medical records better? 2Health News:Sage Products Named a Top Five Medium Sized Company to Work For In America 2Health News:Sage Products Named a Top Five Medium Sized Company to Work For In America 3Health News:Sage Products Named a Top Five Medium Sized Company to Work For In America 4Health News:Employers Express Doubts About Employer Mandate and Government-Sponsored Public Plan, Says Aon Consulting Survey 2Health News:Employers Express Doubts About Employer Mandate and Government-Sponsored Public Plan, Says Aon Consulting Survey 3Health News:Employers Express Doubts About Employer Mandate and Government-Sponsored Public Plan, Says Aon Consulting Survey 4Health News:Employers Express Doubts About Employer Mandate and Government-Sponsored Public Plan, Says Aon Consulting Survey 5
... Many special order products are offered as ... long lengths. The modular instruments may be ... options such as ratchets, insulation and flush ... Mediflex stock. Customer specifications may affect delivery ...
... are offered as 1-piece or modular, in ... instruments may be customized with handles of ... insulation and flush ports. Many standard patterns ... may affect delivery times. , Please ...
... Many special order products are offered as ... long lengths. The modular instruments may be ... options such as ratchets, insulation and flush ... Mediflex stock. Customer specifications may affect delivery ...
... Many special order products are offered as ... long lengths. The modular instruments may be ... options such as ratchets, insulation and flush ... Mediflex stock. Customer specifications may affect delivery ...
Medicine Products: